

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents,

Washington, D.C. 20231, on May 16, 2000

Frank C. Eisenschenk

Frank C. Eisenschenk, Ph.D., Patent Attorney

1644 WIP
(Box 14)
SUBMISSION OF SEQUENCE

LISTING UNDER 1.821

Patent Application

Examining Group 1644

Docket No. SPO-103

Serial No. 09/142,524

RECEIVED

MAY 23 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

AP Unit : 1644
Applicant(s) : Toshio Sone, Akinori Kume, Kazuo Dairiki, Akiko Iwama, Kohsuke Kino
Serial No. : 09/142,524
Filed : September 9, 1998
For : Peptide-based Immunotherapeutic Agent for Treating Allergic Diseases

TECH CENTER 1600/2900

Box SEQUENCE

Assistant Commissioner for Patents

Washington, D.C. 20231

SUBMISSION OF SEQUENCE LISTING UNDER §1.821

Sir:

Transmitted herewith is a sequence listing under 37 CFR §1.821 through 1.825 for the above-identified patent application. A Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures was received from the Patent Office, and a copy of the Notice is enclosed herewith. Also enclosed is an Amendment Under 37 CFR §1.825(a) through (c).

The sequence is submitted in computer readable format and on paper. I hereby certify that the paper and computer readable copies contain the same information and that no new material is added by this submission.

Respectfully submitted,

Frank C. Eisenschenk

Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address : 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606

FCE/la

Attachments: Amendment Under 37 CFR §1.825(a)-(c); Sequence listing on paper and computer readable format containing the same information.